Bio-Rad Laboratories (BIO) Stock Price, Quote & News

Company Profile

Bio-Rad Laboratories, Inc. manufactures and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. It operates through two segments, Life Science and Clinical Diagnostics. The company develops, manufactures, and markets instruments, systems, reagents, and consumables to separate, purify, characterize, and quantitate biological materials, such as cells, proteins, and nucleic acids used in biopharmaceutical manufacturing, q...

Industry: Medical Devices

Sector: Healthcare

Phone: 510 724 7000

Fax: 510 741 5817

Website: www.bio-rad.com

Address:

1000 Alfred Nobel Drive, Hercules, United States

EV_Rebel Aug. 23 at 7:28 AM

$BIO/B Bio-Rad Laboratories Class B non-voting shares with same economic interest

0 · Reply

5GFlipper Aug. 23 at 7:28 AM

$BIO Bio-Rad Laboratories Inc has complex ownership structure and life sciences exposure

0 · Reply

Spicy_Trade Aug. 3 at 4:29 PM

SpicyTrade Bio-Rad Laboratories, Inc. ( $BIO ) daily stock analysis https://youtu.be/85FMTC2bkmI?si=jWwDQ7Qy6YBrvpiJ

0 · Reply

BioTechHealthX Aug. 1 at 6:38 PM

$BIO Bio-Rad Labs rallied after crushing earnings expectations. Learn how process chromatography and ddPCR growth could power even bigger gains. https://biotechhealthx.com/biotech-news/bio-rad-labs-bio-smashes-earnings-estimates-is-the-stock-ready-to-explode/

0 · Reply

topstockalerts Aug. 1 at 3:46 PM

$BIO there she goes…🏦🏦

0 · Reply

JarvisFlow Aug. 1 at 3:23 PM

RBC Capital has adjusted their stance on Bio-Rad Laboratories ( $BIO ), setting the rating to Outperform with a target price of 387 → 409.

0 · Reply

topstockalerts Aug. 1 at 2:13 PM

Top Gainers PT2 $LXEH $TILE $ANTE $FDMT $BIO

0 · Reply

d_risk Aug. 1 at 1:50 PM

$BIO - Bio-Rad Laboratories Inc. Class A Common Stock - 10Q - Updated Risk Factors BIO’s 2025 10-Q reveals heightened risks from complex global compliance, supply chain and innovation delays, geopolitical and economic instability, cyber and IT disruptions, currency volatility, regulatory shifts, organizational changes, tax reforms, ESG pressures, rising debt, and intensified litigation exposure. #Biotechnology #GeopoliticalInstability #Cybersecurity #SupplyChainRisk #GlobalCompliance 🟢 Added 🟠 Removed https://d-risk.ai/BIO/10-Q/2025-07-31

0 · Reply

topstockalerts Aug. 1 at 12:11 PM

$BIO where's she going once market opens? ..🍾🍾 ..

0 · Reply

jbess22 Aug. 1 at 1:05 AM

$PSTV $BIO $UNH $BGLC

0 · Reply

Bio-Rad Laboratories: Macroeconomic Uncertainty And A Limited Growth Potential Give Pause

Aug 1, 2025, 11:30 AM EDT - 23 days ago

Bio-Rad Laboratories Analysts Raise Their Forecasts After Better-Than-Expected Q2 Earnings

Aug 1, 2025, 9:00 AM EDT - 23 days ago

Bio-Rad to Host Droplet Digital PCR Webinar on Tuesday, August 26, 2025

Jul 31, 2025, 9:55 PM EDT - 24 days ago

Bio-Rad Laboratories, Inc. (BIO) Q2 2025 Earnings Call Transcript

Jul 31, 2025, 4:15 PM EDT - 24 days ago

Bio-Rad Reports Second-Quarter 2025 Financial Results

Jul 28, 2025, 4:15 PM EDT - 27 days ago

Bio-Rad Appoints Rajat Mehta Executive Vice President, Global Commercial Operations

Jul 17, 2025, 4:15 PM EDT - 5 weeks ago

Bio-Rad to Report Second Quarter 2025 Financial Results on Thursday, July 31, 2025

Jul 7, 2025, 9:00 AM EDT - 6 weeks ago

Bio-Rad Expands Droplet Digital PCR Offering Through Strategic Acquisition and Platform Rollout

May 29, 2025, 4:30 PM EDT - 3 months ago

Bio-Rad's Management to Host Investor Meetings During Jefferies Global Healthcare Conference

May 12, 2025, 4:30 PM EDT - 3 months ago

Bio-Rad's Management to Participate in Fireside Chat During 2025 RBC Capital Markets Global Healthcare Conference

May 1, 2025, 10:35 PM EDT - 4 months ago

Bio-Rad Laboratories, Inc. (BIO) Q1 2025 Earnings Call Transcript

May 1, 2025, 4:15 PM EDT - 4 months ago

Bio-Rad Reports First-Quarter 2025 Financial Results

Feb 13, 2025, 11:45 PM EST - 6 months ago

Bio-Rad Laboratories, Inc. (BIO) Q4 2024 Earnings Call Transcript

Feb 13, 2025, 4:20 PM EST - 6 months ago

Bio-Rad Reports Fourth-Quarter and Full-Year 2024 Financial Results

Feb 13, 2025, 4:15 PM EST - 6 months ago

Bio-Rad Offers to Acquire Digital PCR Developer Stilla Technologies

Jan 27, 2025, 5:00 PM EST - 7 months ago

Bio-Rad to Report Fourth Quarter and Full Year 2024 Financial Results on Thursday, February 13, 2025

Jan 8, 2025, 8:15 AM EST - 8 months ago

Geneoscopy Closes $105M in Series C Funding Round to Power Next-Generation of Gastrointestinal Diagnostic Tests

Jan 2, 2025, 4:30 PM EST - 8 months ago

Bio-Rad's Management to Host Investor Meetings at J.P. Morgan's 43rd Annual Healthcare Conference

Nov 21, 2024, 9:00 AM EST - 9 months ago

Bio-Rad's Management to Host Investor Meetings at Citi's 2024 Global Healthcare Conference

Oct 31, 2024, 9:00 AM EDT - 10 months ago

Bio-Rad's Management to Participate in Fireside Chat During UBS Global Healthcare Conference

Oct 30, 2024, 8:22 PM EDT - 10 months ago

Bio-Rad Laboratories, Inc. (BIO) Q3 2024 Earnings Call Transcript

Oct 30, 2024, 6:09 PM EDT - 10 months ago

Bio-Rad Laboratories beats quarterly profit estimates on strong sales in diagnostics unit

Oct 30, 2024, 4:15 PM EDT - 10 months ago

Bio-Rad Reports Third-Quarter 2024 Financial Results

Oct 14, 2024, 5:30 PM EDT - 11 months ago

Bio-Rad to Report Third Quarter 2024 Financial Results on Wednesday, October 30, 2024

Sep 6, 2024, 6:43 PM EDT - 1 year ago

Palantir Technologies, Dell Technologies, and Erie Indemnity Set to Join S&P 500; Others to Join S&P MidCap 400 and S&P SmallCap 600

ADNT CHCT CMP CNH DBI DDD DELL

Aug 22, 2024, 4:30 PM EDT - 1 year ago

Bio-Rad's Management to Participate in Fireside Chat During Wells Fargo's 2024 Healthcare Conference

Aug 20, 2024, 8:30 AM EDT - 1 year ago

Bio-Rad Appoints Jon DiVincenzo President, Chief Operating Officer

Aug 1, 2024, 10:47 PM EDT - 1 year ago

Bio-Rad Laboratories, Inc. (BIO) Q2 2024 Earnings Call Transcript

Aug 1, 2024, 5:56 PM EDT - 1 year ago

Bio-Rad Labs cuts annual revenue forecast on weak demand for diagnostics products

Aug 1, 2024, 4:15 PM EDT - 1 year ago

Bio-Rad Reports Second-Quarter 2024 Financial Results

Jul 17, 2024, 4:30 PM EDT - 1 year ago

Bio-Rad to Report Second Quarter Financial Results on Thursday, August 1, 2024

May 30, 2024, 9:00 AM EDT - 1 year ago

Bio-Rad Names Anette Engelhardt Executive Vice President and President of Clinical Diagnostics Group

May 23, 2024, 4:15 PM EDT - 1 year ago

Bio-Rad's Management to Participate in Fireside Chat During Jefferies Global Healthcare Conference

May 7, 2024, 11:16 PM EDT - 1 year ago

Bio-Rad Laboratories, Inc. (BIO) Q1 2024 Earnings Call Transcript

May 7, 2024, 6:11 PM EDT - 1 year ago

Bio-Rad Laboratories reiterates 2024 revenue growth outlook; shares slip

May 7, 2024, 4:15 PM EDT - 1 year ago

Bio-Rad Reports First-Quarter 2024 Financial Results

May 1, 2024, 9:00 AM EDT - 1 year ago

Bio-Rad's Management to Participate in Fireside Chat During RBC Capital Markets Global Healthcare Conference

Apr 26, 2024, 8:30 AM EDT - 1 year ago

Bio-Rad Announces Life Science Group Management Changes

Apr 18, 2024, 9:00 AM EDT - 1 year ago

Bio-Rad to Report First Quarter 2024 Financial Results on Tuesday, May 7, 2024

Apr 10, 2024, 4:15 PM EDT - 1 year ago

Bio-Rad's Chief Operating Officer Andrew Last to Retire

Mar 20, 2024, 8:30 AM EDT - 1 year ago

Bio-Rad Appoints Roop K. Lakkaraju Executive Vice President, Chief Financial Officer

Feb 22, 2024, 4:30 PM EST - 1 year ago

Bio-Rad to Participate in Fireside Chat During Citi's 2024 Unplugged Medtech and Life Sciences Access Day

Feb 15, 2024, 6:54 PM EST - 1 year ago

Bio-Rad Laboratories, Inc. (BIO) Q4 2023 Earnings Call Transcript

Feb 15, 2024, 6:51 PM EST - 1 year ago

Bio Rad Labs rises after posting upbeat fourth-quarter profit

Feb 15, 2024, 4:15 PM EST - 1 year ago

Bio-Rad Reports Fourth-Quarter and Full-Year 2023 Financial Results

Jan 24, 2024, 5:00 PM EST - 1 year ago

Bio-Rad to Report Fourth Quarter and Full Year 2023 Financial Results on Thursday, February 15, 2024

Jan 2, 2024, 4:15 PM EST - 1 year ago

Bio-Rad's Management to Host Investor Meetings at J.P. Morgan's 42nd Annual Healthcare Conference

Dec 26, 2023, 11:29 AM EST - 1 year ago

S&P 500 Stocks With the Most Upside

APA APTV FSLR GM HAL LVS MRNA

Dec 20, 2023, 3:07 PM EST - 1 year ago

6 Stock Picks in Healthcare for 2024

BMY CI HUM INCY MRNA

Oct 26, 2023, 8:04 PM EDT - 1 year ago

Bio-Rad Laboratories, Inc. (BIO) Q3 2023 Earnings Call Transcript

EV_Rebel Aug. 23 at 7:28 AM

$BIO/B Bio-Rad Laboratories Class B non-voting shares with same economic interest

0 · Reply

5GFlipper Aug. 23 at 7:28 AM

$BIO Bio-Rad Laboratories Inc has complex ownership structure and life sciences exposure

0 · Reply

Spicy_Trade Aug. 3 at 4:29 PM

SpicyTrade Bio-Rad Laboratories, Inc. ( $BIO ) daily stock analysis https://youtu.be/85FMTC2bkmI?si=jWwDQ7Qy6YBrvpiJ

0 · Reply

BioTechHealthX Aug. 1 at 6:38 PM

0 · Reply

topstockalerts Aug. 1 at 3:46 PM

$BIO there she goes…🏦🏦

0 · Reply

JarvisFlow Aug. 1 at 3:23 PM

RBC Capital has adjusted their stance on Bio-Rad Laboratories ( $BIO ), setting the rating to Outperform with a target price of 387 → 409.

0 · Reply

topstockalerts Aug. 1 at 2:13 PM

Top Gainers PT2 $LXEH $TILE $ANTE $FDMT $BIO

0 · Reply

d_risk Aug. 1 at 1:50 PM

0 · Reply

topstockalerts Aug. 1 at 12:11 PM

$BIO where's she going once market opens? ..🍾🍾 ..

0 · Reply

jbess22 Aug. 1 at 1:05 AM

$PSTV $BIO $UNH $BGLC

0 · Reply

John_Wick1234 Jul. 28 at 11:03 AM

$BIO Nice Double Bottom.

1 · Reply

JarvisFlow Jul. 15 at 11:00 AM

Wells Fargo updates rating for Bio-Rad Laboratories ( $BIO ) to Equal-Weight, target set at 340 → 360.

0 · Reply

Darbye Jul. 14 at 5:31 PM

$HPIL $BIO Im not going to be able to watch the Shareholders conference. 😟 So, whomever does watch, please take notes or just remember the good stuff. 😆 Im sure theres a few of us that can't watch. Or just tell us that we're going to be Rich. 🤑 Thank you 🙏

2 · Reply

John_Wick1234 Jul. 14 at 12:54 PM

$BIO Double Bottom With Good Volume.

0 · Reply

ZacksResearch Jul. 14 at 12:43 PM

$BIO just launched 4 new ddPCR platforms — shares have risen 4% since the announcement. 🔍 Bio-Rad's new products, including the QX Continuum system, aim to strengthen its Life Science segment by offering unparalleled workflow simplicity and throughput capabilities. This expansion is expected to boost market sentiment around the stock. Discover the full story here 👉 https://www.zacks.com/stock/news/2579353/bio-rad-stock-climbs-following-the-launch-of-four-ddpcr-platforms?cid=sm-stocktwits-2-2579353-body-1496&ADID=SYND_STOCKTWITS_TWEET_2_2579353_BODY_1496

0 · Reply

ZacksResearch Jul. 14 at 11:08 AM

$BIO pops 4% on major product launch — is this the growth spark investors needed? The Stilla acquisition just paid off, powering the rollout of four new ddPCR systems and pushing the assay menu past 400K. Full story here 👉 https://www.zacks.com/stock/news/2579353/bio-rad-stock-climbs-following-the-launch-of-four-ddpcr-platforms?cid=sm-stocktwits-2-2579353-teaser-1461&ADID=SYND_STOCKTWITS_TWEET_2_2579353_TEASER_1461

0 · Reply

_CCS_ Jun. 23 at 7:53 PM

$BIO bull trap after trap

0 · Reply

leavens123 May. 28 at 2:01 PM

$VERU not a matter of if, it’s when. This is bound to pass phase 2 and clinical. GLP1 is everywhere now. So muscle wasting from its use will need this big time. $SPRB $BIO $SBIO

0 · Reply

DerEins May. 27 at 6:11 PM

$BIO Earnings have been good, upbeat the expected by 40%, the way down has been long for this now, if i look at the charts, a turningpoint might come.... so i jumped in today a bit, lets see how good my guess will be :-)

0 · Reply

SamwiseTheBrave May. 19 at 3:24 PM

$SPY $BIO has decided not to eat it 🤣

1 · Reply

Bgarr231 May. 7 at 11:31 PM

$BIO debating if i should avg down here or not...

0 · Reply

JarvisFlow May. 2 at 11:00 PM

UBS has updated their rating for Bio-Rad Laboratories ( $BIO ) to Buy with a price target of 310.

0 · Reply

Market Cap	8.22B
Revenue (ttm)	2.57B
Net Income (ttm)	-1.84B
EPS (ttm)	N/A
PE Ratio	28.33
Forward PE	30.88
Profit Margin	-71.86%
Debt to Equity Ratio	0.17

Volume	783,300
Avg Vol	336,214
Day's Range	N/A - N/A
Shares Out	27.06M
Stochastic %K	90%
Beta	0.90
Analysts	Sell
Price Target	$325.80